Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice


News provided by

Almirall, S.A.

06 Oct, 2021, 09:35 GMT

Share this article

Share toX

Share this article

Share toX

- Psoriasis affects the overall emotional wellbeing of 88% of patients[1], and at least 20% of psoriasis patients have considered suicide[2]

- Currently used endpoints in psoriasis do not capture the full impact of this skin condition on patients' lives, and almost 50% of them feel that their healthcare professionals do not understand the mental health impact of the disease[3]

- In addition to clinical manifestations, experts believe that an overall assessment of the wellbeing of the patient is crucial and that such evaluation should be implemented in clinical practice

- Almirall is initiating the innovative POSITIVE study, which, for the first time, assesses the improvement in the overall wellbeing of psoriasis patients treated with tildrakizumab[4] in a real-world setting

BARCELONA, Spain, Oct. 6, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, has hosted a scientific session during the 30th EADV (European Association of Dermatology and Venereology) Congress which addressed the need and importance to focus on patient wellbeing in real-life clinical practice. The symposium was part of Almirall's participation in the congress, which consisted of 21 posters and four scientific sessions.

Psoriasis is one of the most prevalent skin conditions in the world and it affects the overall emotional wellbeing of 88% of patients1,and at least 20% of them have considered suicide2. In this regard, according to the World Psoriasis Happiness Report 2018, only 27% report that their doctor talked to them about mental health. Additionally, almost 50% of psoriasis patients feel that their healthcare professionals don't understand the impact that the disease has on their mental health.3

In the symposium titled "Are you wasting your time getting to PASI100?", Prof. Piaserico (Italy) together with Prof. Mrowietz (Germany) and the happiness scientist Prof. Quoidbach (Spain), addressed questions on psoriasis patients' true needs and wellbeing. The experts pointed out that, in addition to manage the disease's clinical manifestations, the clinical practice should implement an overall and holistic assessment of the wellbeing of each patient. "The endpoints that are currently being used, such as PASI and DLQI, do not capture correctly the full impact of psoriasis on patients' life", stated Prof. Stefano Piaserico, Associate Professor at the University of Padua, Italy and Head of the Regional Centre for Psoriasis.

As a first step to measure the value of a treatment on the overall wellbeing of the patient, Prof. Quoidbach brought up some practical tips that dermatologists could implement in their clinical practice, for instance asking questions like "How do you feel?  Do you feel okay?  Do you feel happy?". The speakers also outlined that it is crucial to take into account the long-term control of psoriasis  given the chronicity of the disease. In this context, Prof. Ulrich Mrowietz, Head of the Psoriasis-Center at the University Medical Center Schleswig-Holstein, presented the design of the innovative POSITIVE study, which assesses the improvement in the overall wellbeing of psoriasis patients treated with tildrakizumab3.

The overall wellbeing of a patient and the holistic approach of people-centred healthcare has never been measured in a robust prospective psoriasis study. To assess patient wellbeing, this study will apply the 5-item WHO Well-being Index (WHO-5), a widely used questionnaire assessing the subjective psychological health-related wellbeing in a variety of chronic diseases such as diabetes, cardiovascular disease, cancer, and depression. For the first time, WHO-5 will be tested as a primary endpoint in patients with psoriasis to capture the effect that tildrakizumab can have on patients' wellbeing in a real-world setting. Moreover, the long-term response on physicians' satisfaction and psoriasis patients' partners' lives will also be evaluated.

Tildrakizumab was chosen for this study as a representative of the anti-IL-23 class biologics, that block the key master cytokine in the pathogenesis of plaque psoriasis.

"Providing patients with real solutions that improve their health and wellbeing is at the core of everything we do at Almirall. The symposium has explored outcomes that truly matter to patients and their wellbeing in the context of commonly used regulatory endpoints. With advanced modern therapies now widely available to HCPs, Almirall believes that it is important to also advance our understanding of truly meaningful and ambitious outcomes for our patients," states Volker Koscielny, Chief Medical Officer at Almirall.

About tildrakizumab[5]

Tildrakizumab is a humanized monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23) and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

[1] Armstrong AW, Schupp C, Wu J, et al. PLoS One. 2012;7(12):e52935; 2. National Psoriasis Foundation 2008 Survey Snapshot. Available from: http://www.psoriasis.org/document.doc?id=193.; 3. Krueger G, Koo J, Lebwohl M, et al. Arch Dermatol. 2001;137(3):280-284.

[2] Krueger G, Koo J, Lebwohi M, et al. Arch Dermatol. 2001;137(3):280-284

[3] The Health & Happiness Research Foundation (2018) World Psoriasis Happiness Report 2018. Available at: https://psoriasishappiness.report/

[4] Augustin M, Sommer R, Massana E, et al. on behalf of the POSITIVE investigators. Patient-reported wellbeing in value-based care using tildrakizumab in a real world setting: The POSITIVE Study. Poster number P1493. Presented at 30th EADV Congress; 29 Sept - 2 Oct: 2021.

[5] IlumetriI® (tildrakizumab) Summary of Product Characteristics.  

Date of prep: October 2021 UK-IL-2100111

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.